TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Altimmune ( (ALT) ) has issued an update.
On December 1, 2025, Altimmune announced a CEO transition plan where Vipin K. Garg, Ph.D., will step down as President and CEO effective January 1, 2026, with Jerome Durso taking over the role. Dr. Garg will remain as an advisor until June 30, 2026, to ensure a smooth transition. Under Dr. Garg’s leadership since 2018, Altimmune advanced its lead candidate, pemvidutide, to a Phase 3 ready program for MASH. The transition is expected to continue the company’s growth and focus on pemvidutide’s potential benefits for liver disease patients.
The most recent analyst rating on (ALT) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score is primarily influenced by its financial challenges, with severe profitability issues and cash flow difficulties. However, the positive sentiment from the earnings call and technical indicators showing bullish momentum provide some optimism. The valuation remains weak due to negative earnings and no dividend yield.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and metabolic diseases. Its lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
Average Trading Volume: 2,831,596
Technical Sentiment Signal: Hold
Current Market Cap: $548.8M
For detailed information about ALT stock, go to TipRanks’ Stock Analysis page.